165.00
前日終値:
$174.00
開ける:
$172.695
24時間の取引高:
7.00M
Relative Volume:
2.25
時価総額:
$22.10B
収益:
$4.29B
当期純損益:
$577.22M
株価収益率:
39.21
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
-26.35%
1か月 パフォーマンス:
-33.13%
6か月 パフォーマンス:
-46.69%
1年 パフォーマンス:
-63.30%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals Inc
|
165.00 | 22.10B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
VRTX
Vertex Pharmaceuticals Inc
|
558.88 | 141.65B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
927.89 | 95.53B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
221.72 | 88.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
892.87 | 56.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
370.33 | 41.89B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-15 | 再開されました | UBS | Buy |
| 2026-08-19 | 開始されました | BMO Capital Markets | Outperform |
| 2026-08-03 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2026-05-19 | 開始されました | Citigroup | Buy |
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates - Zacks Investment Research
UBS cuts target for Alnylam Pharmaceuticals stock from USD 550.00 to USD 354.00 - ad-hoc-news.de
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - Yahoo Finance
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView
Alnylam Pharmaceuticals, Inc.- RNAi Roundtable Transcript - GuruFocus
Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case (NASDAQ:ALNY) - Seeking Alpha
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Alnylam Pharmaceuticals Inc. Research & Ratings | ALNY - Barron's
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Hun - Alnylam
Alnylam Lobbying Rises Amid Medicare Drug Pricing Debate - Legis1
Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Results for Huntington's Disease Therapy - GuruFocus
Alnylam Pharmaceuticals, Inc. Estimates – NASDAQ:ALNY - TradingView
Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Data f - GuruFocus
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued - Simply Wall Street
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - Yahoo Finance
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? - Yahoo Finance
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered - The National Law Review
ALNYLAM PHARMACEUTICALS INC (ALNY.MX) Q4 FY2025 earnings call transcript - Yahoo Finance
What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall - Simply Wall Street
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum - ChartMill
Alnylam Pharmaceuticals, Inc. (ALNY) options chain - Yahoo Finance Australia
UBS Adjusts Alnylam Pharmaceuticals Price Target to $354 From $550, Maintains Buy Rating - Yahoo Finance
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results - Alnylam
Alnylam Pharmaceuticals (NASDAQ:ALNY) Share Price, Forecast & Analysis - Stocks Down Under
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Yahoo Finance
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
BofA Securities Adjusts Alnylam Pharmaceuticals Price Target to $336 From $346 - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide - Yahoo Finance
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value? - Yahoo Finance
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Peri - Alnylam
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - wboc.com
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SUPRAN BRYAN | Officer |
Oct 02 '26 |
Proposed Sale |
226.88 |
1,758 |
398,862 |
0 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
3,830 |
0 |
5,412 |
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Proposed Sale |
299.51 |
3,830 |
1,147,123 |
0 |
| SCHULMAN AMY W | Director |
May 13 '26 |
Option Exercise |
70.20 |
11,250 |
789,750 |
23,211 |
| McLaughlin Melissa | Officer |
Apr 06 '26 |
Proposed Sale |
320.10 |
2,286 |
731,749 |
0 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 06 '26 |
Sale |
330.42 |
2,286 |
755,329 |
9,443 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | Officer |
Mar 05 '26 |
Proposed Sale |
323.69 |
658 |
212,988 |
0 |
大文字化:
|
ボリューム (24 時間):